Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Mexico - Delayed Quote MXN

bluebird bio, Inc. (BLUE.MX)

Compare
80.00
0.00
(0.00%)
As of March 3 at 1:43:52 PM CST. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for BLUE.MX

Recent News: BLUE.MX

View More
Gene therapy maker bluebird to go private in discounted deal amid cash crunch

Gene therapy maker bluebird to go private in discounted deal amid cash crunch
Reuters 13 days ago
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital

bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital
Business Wire 13 days ago
bluebird bio, Inc. (BLUE): Is This Gene Therapy Stock a Good Buy Right Now?

bluebird bio, Inc. (BLUE): Is This Gene Therapy Stock a Good Buy Right Now?
Insider Monkey 2 months ago
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
Business Wire 2 months ago
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels

Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
Business Wire 2 months ago
bluebird bio Announces 1-for-20 Reverse Stock Split

bluebird bio Announces 1-for-20 Reverse Stock Split
Business Wire 2 months ago
bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model

bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model
Business Wire 2 months ago
bluebird bio Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

bluebird bio Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Simply Wall St. 3 months ago
bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
Business Wire 3 months ago
bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call

bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call
Business Wire 3 months ago
bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
Business Wire 3 months ago
View More

Related Tickers

RVU.WA Ryvu Therapeutics S.A.
19.94
-6.16%
 
MIR.V MedMira Inc.
0.1050
0.00%
 
ORY.MC Oryzon Genomics S.A.
2.8350
-0.53%
 
ANNX Annexon, Inc.
2.7100
-1.81%
 
CELU Celularity Inc.
1.3450
-1.82%
 
ADPT Adaptive Biotechnologies Corporation
7.77
-3.24%
 
PTCT PTC Therapeutics, Inc.
51.80
-0.25%
 
MIST Milestone Pharmaceuticals Inc.
1.9300
-2.52%
 
IBRX ImmunityBio, Inc.
2.9850
-2.45%
 
IOVA Iovance Biotherapeutics, Inc.
3.8000
-6.17%